Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:acquiredBy |
gptkb:Boston_Scientific
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:formerName |
gptkb:British_Technology_Group
|
| gptkbp:founded |
1948
|
| gptkbp:headquarters_location |
gptkb:London,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
BTG plc
|
| gptkbp:industry |
healthcare
pharmaceuticals |
| gptkbp:keyPerson |
gptkb:Louise_Makin
gptkb:Rolf_Soderstrom |
| gptkbp:listedOn |
gptkb:FTSE_250_Index
|
| gptkbp:notableProduct |
antidotes
oncology treatments embolization devices interventional medicine |
| gptkbp:numberOfEmployees |
~1400 (2018)
|
| gptkbp:stockExchange |
gptkb:London_Stock_Exchange
|
| gptkbp:stockSymbol |
gptkb:BTG
|
| gptkbp:website |
https://www.btgplc.com/
|
| gptkbp:bfsParent |
gptkb:abiraterone
gptkb:BTG |
| gptkbp:bfsLayer |
6
|